Lv53
1560 积分 2024-08-22 加入
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
14天前
已完结
TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens
16天前
已完结
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
21天前
已完结
International approvals of cilta-cel: a lens on CAR T cell regulation
1个月前
已完结
Exclusive: These universities have the most retracted scientific articles
1个月前
已完结
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma
1个月前
已完结
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53
1个月前
已完结
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
3个月前
已完结
In vivo CAR T cells move into clinical trials
3个月前
已完结
Accelerating and optimising CAR T-cell manufacture to deliver better patient products
4个月前
已完结
皖公网安备34019202002308
